This study revealed that cancer and chemotherapy do not appear to increase the risk of stillbirth, providing critically important information for women who are worried about their ability to deliver a healthy child after cancer.”

For one of the co-authors of the paper, Andrea C. Betts, PhD, MPH, the findings were personal.

"When I was pregnant with my first child, there was very little information about how my past treatment for cancer could affect my child,” said Betts, a researcher with the school’s Dallas campus. “All my OB could tell me was, 'It's plausible there are increased risks.' It's so rewarding to begin to close this gap in the evidence, and provide some good news to the many young women seeking to have children after cancer."

Previous studies have suggested that the health of the offspring might be affected. To test that theory, the study linked population-based data from the Texas Cancer Registry to live birth and fetal death certificates. They included 11,696 deliveries to 8,402 women ages 15 to 39 years who were diagnosed with cancer from 1995 to 2015 and compared them to the rate of stillbirth in the general population. The rate of stillbirth in both groups was similar, less than 1%.

“It’s the best kind of null result,” Murphy said.

Along with Betts, co-authors from UTHealth School of Public Health included Marlyn A. Allicock, PhD, MPH, of the Dallas campus; L. Aubree Shay, PhD, MSW, of the San Antonio campus; and Sharice M. Preston, PhD, of the Houston campus.

All are part of a team of investigators in the Adolescent and Young Adult (AYA) Scholarship, Training, and Research (STAR) Lab that formed at UTHealth School of Public Health in 2020. Their expertise includes behavioral sciences, intervention development, epidemiology, program evaluation, and health disparities.

(SM/NEWSWISE)